Tag
The Phase 3b DELIVER trial confirms that both the dapivirine vaginal ring and oral PrEP are safe and well-tolerated when initiated in the second trimester of pregnancy, showing no product-related serious adverse events and high rates of ter
In a randomized phase 3b trial of pregnant women using the dapivirine vaginal ring or daily oral TDF/FTC for HIV prevention, 12‑month infant follow‑up showed no product‑related serious or grade 3+ adverse events and no HIV transmissions, su
An observational study evaluates an AI chatbot’s usability in promoting HIV testing among men who have sex with men in Malaysia, showcasing potential improvements for public health interventions.
Lenacapavir (Yeztugo) becomes the first FDA-approved, twice-yearly injectable PrEP, offering robust long-acting HIV prevention and addressing key adherence barriers.
